news

Reporter: Zhao Yangge

The Shanghai and Shenzhen stock markets are currently conducting review work in an alternating manner. In the week between July and August, the Shanghai Stock Exchange arranged a company to go to the meeting, and in the first week of August, the Shenzhen Stock Exchange completed the review of a company. This week, it is the turn of the Shanghai Stock Exchange to "start work" again. The 20th meeting of 2024 will be held on August 16. The review targets are companies that plan to enter the Science and Technology Innovation Board.Jiangsu Pioneer Precision Technology Co., Ltd. (hereinafter referred to as Pioneer Precision).

Pioneer Precision:Domestic small quantity production supply7nmAnd the following key components of domestic etching equipment

From the Shanghai Stock Exchange website,Pioneer Precision accepted the case on June 8, 2023, and completed two rounds of inquiries.It will go to the meeting on August 16. The sponsor is Huatai Securities and the planned financing amount is 587 million yuan.

It is reported that,Pioneer Precision isThe company is an expert in precision manufacturing of key components in the domestic semiconductor etching and thin film deposition equipment segments. In particular, the company is one of the few domestic companies that has mass-produced and supplied etching equipment, which is recognized by the industry as second only to photolithography equipment in terms of technical difficulty.7nmThe company is a supplier of key components of domestic etching equipment and competes directly with international manufacturers. In addition, the company is also exploring and developing new products in other fields such as photovoltaics and medical treatment.

Its operating income in 2023 was 558 million yuan, and its net profit was 80.285 million yuan; it is expected to have operating income of 548 million yuan and net profit of 112 million yuan in the first half of 2024.2020to2022In 2018, the issuer's cash dividends totaled10798.01Ten thousand yuan.

However, it should be pointed out that the company's performance fluctuated. While its operating income increased by 18.68% year-on-year in 2023, its non-net profit decreased by 19.37% year-on-year.The main reason is that the overall gross profit margin decreased year-on-year9.23%。andThe decline in gross profit margin is due to the combined effects of the strong cyclicality of semiconductors and external technological blockades.2023The capital expenditure of major domestic wafer fabs temporarily decreased in 2018, which led to a decrease in direct customer demand for the company's products, a decrease in the capacity utilization rate of the company's semiconductor products, and a decrease in gross profit margin.；On the other hand, the proportion of products in the photovoltaic field has increased, while its gross profit margin is relatively low, further lowering the overall gross profit margin.

also,Pioneer Precision has a high customer concentration, with the top five customers accounting for more than 80%, the company explainedThe main reason is that the semiconductor industry is highly technology and capital intensive, resulting in a small number of downstream equipment companies and wafer foundry companies with large scale.

Juxing Technology plans to raise 243 million yuan

The Beijing Stock Exchange's Listing Committee also has a review plan this week. It will hold the 13th meeting of 2024 on August 16. The review object will be Juxing Technology (874021.NQ).

Juxing Technology is sponsored by SDIC Securities and was listed on February 16, 2023. It is currently listed on the Innovation Board.The main business is the research and development, production and sales of electrical contact products. The main products are electrical contacts and electrical contact components, which are the main source of operating income. In addition, the company's electrical contact products also include electrical contact materials, which are the core raw materials for the production of electrical contacts and electrical contact components. The electrical contact materials produced by the company are mainly used for the production of electrical contacts and electrical contact components, and a small amount is used for external sales.

According to statistics from the Electrical Alloy Branch of the China Electrical Equipment Industry Association,2021Year to2023year,Juxing TechnologyThe domestic market share of rivet-type electrical contacts has ranked first for three consecutive years(According to sales quantity)The company has already cooperated with Chun Lu Shou Company and Hong Fa Shares(600885.SH), Bull Group(603195.SH), Sanyou Lianzhong(300932.SZ), Meishuo Technology(301295.SZ), Shenle Co., Ltd., Hongshi Electric, Zettler Electronics and other well-known companies in the industry have cooperated.

Juxing Technology's operating income in 2023 was 603 million yuan, and its net profit was 76.7562 million yuan; in the first half of 2024, the company achieved operating income of 436 million yuan, a year-on-year increase of 65.35%, and net profit of 48.64 million yuan, a year-on-year increase of 32.46%.

This time,Juxing Technology plans to raise 243 million yuan, invest 152 million yuan in the "production line intelligent technology transformation project", 51.1167 million yuan in the "R&D center construction project", and supplement 40 million yuan in working capital.

Haoyuan Pharmaceutical raised 1.161 billion yuan and achieved an additional net profit of 221 million yuan after reaching full production

In addition, there are listed companies in the Shanghai Stock ExchangeThe convertible bond project of Haoyuan Pharmaceutical (688131.SH) will be reviewed on August 13, with a financing amount of 1.161 billion yuan.

Haoyuan Pharmaceutical will be listed on June 8, 2021.It is a company that focuses on providing professional and efficient small molecule and new molecule drugs to the global pharmaceutical and biopharmaceutical industries.CRO&CDMOThe company is a high-tech platform enterprise that provides services. Its main businesses include the research and development of molecular building blocks and tool compounds in the field of small molecule and new molecule drug discovery, process development and production technology improvement of small molecule and new molecule drug APIs and intermediates, as well as pharmaceutical research and development, registration and production of preparations. The company currently has about7000Home partners.

but2023YearHaoyuan Pharmaceutical's performance declined, with a net profit of 127 million yuan, a year-on-year decrease of 34.18%. The net profit in the first quarter of 2024 was 16.7574 million yuan, a year-on-year decrease of 63.76%. Its semi-annual report will be disclosed on August 29.

Haoyuan Pharmaceutical plans to raise 1.161 billion yuan this time and invest it in five projects.Anhui Haoyuan Pharmaceutical Co., Ltd.121.095Tons of pharmaceutical raw materials and intermediates construction project(Phase II)”cast2.38100 million yuan,“High-end pharmaceutical intermediates and APIsCDMOIndustrialization Project(Phase I)”cast3.73100 million yuan,“265t/aHigh-end pharmaceutical intermediates product project”cast1.24Billions of yuan, "Ochuang Biotechnology New Drug Technology R&D Center”Investment7985Ten thousand yuan, the rest3.45Billion yuan to supplement working capital.

Interface News noted thatHaoyuan PharmaceuticalAnhui Haoyuan Pharmaceutical Co., Ltd.121.095Tons of pharmaceutical raw materials and intermediates construction project(Phase II)”, Construction period30Months, payback period7.83Years (including construction period),The average net profit after reaching full production is expected to be8945.71Ten thousand yuan.

“High-end pharmaceutical intermediates and APIsCDMOIndustrialization Project(Phase I)”The overall construction period is24months, the estimated internal rate of return after income tax is16.91%The payback period is7.59Year(Including construction period), the average net profit after reaching full production is expected to be about9661.21Ten thousand yuan.

“265t/aHigh-end pharmaceutical intermediates product project”The overall construction period is27The average net profit after reaching full production is expected to be3513.98Ten thousand yuan.

In other words, the three projects will generate a total of 221 million yuan in net profit when they reach full production, which is 1.74 times the company's net profit in 2023.